Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.
Willing EM, Vollbrecht C, Vössing C, Weist P, Schallenberg S, Herbst JM, Schatz S, Jóri B, Bataillon G, Harter P, Salutari V, Martin AG, Vergote I, Colombo N, Roeper J, Berg T, Berger R, Kah B, Noettrup TJ, Falk M, Arndt K, Polten A, Ray-Coquard I, Selzam F, Pirngruber J, Schmidt S, Hummel M, Tiemann M, Horst D, Sehouli J, Pujade-Lauraine E, Tiemann K, Braicu EI, Heukamp LC. Willing EM, et al. Among authors: roeper j. Cancers (Basel). 2023 Jun 30;15(13):3445. doi: 10.3390/cancers15133445. Cancers (Basel). 2023. PMID: 37444554 Free PMC article.
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Among authors: roeper j. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.
Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Brückner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: roeper j. Lung Cancer. 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007. Epub 2020 Aug 22. Lung Cancer. 2020. PMID: 32871455
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
Boch T, Frost N, Sommer L, Overbeck TR, Michaeli CT, Szuszies CJ, Rieckmann LM, Beumer N, Imbusch CD, Winter H, Thomas M, Roeper J, Janning M, Griesinger F, Wermke M, Loges S. Boch T, et al. Among authors: roeper j. Lung Cancer. 2022 Feb;164:46-51. doi: 10.1016/j.lungcan.2021.11.009. Epub 2021 Nov 23. Lung Cancer. 2022. PMID: 34998106
102 results